化学療法剤の適切な使い方について
|
|
|
- しげじろう こうい
- 9 years ago
- Views:
Transcription
1
2 5 6 7 Che E, in Cancer: Principles & Practice of Oncology (7th ed) in Devita, 2005 Marangolo M, Oncol Rep, 2006 hryniuk WM, Important Adv Oncol, Cancer: Principles & Practice of Oncology 5th Ed. Devita, 1997
3 9 Rassnick KM, Vet Comp Oncol, 2010 Vaughan A, JVIM, 2007 Frimberger AE, JVIM, IIIVn= 66 L-CHOP-CCNU-MOPP p= 0.05 L-CHOP Rassnick KM, Vet Comp Oncol, IIIVn= Vaughan A, JVIM, IIIVn= 28 VELCAP p= Frimberger AE, JVIM, 2006
4 13 14 CCNU (70mg/m 2 ) CCNU(60mg/m 2 ) CCNU (60mg/m 2 ) CCNU (60mg/m 2 ) SD PR CR Grade4 Seg= 37 Grade4 Seg= 34 Grade4 Seg= 251 Grade4 Seg= kg 16
5 17 Ogilvie GK, JAVMA, !20 PDGFR= VEGFR= PDGF PDGF & PDGFR-β binding VEGF PDGFR-β トセラニブ VEGF & VEGFR-2 binding VEGFR-2 トセラニブ
6 21 London CA, Vet Compar Oncol, n= 85 % n=32 n=23 n=15 n=8 n=7 London CA, Vet Compar Oncol, n= 85 London CA, Vet Compar Oncol,
7 25!26 27 Samm, 2010 Phillips, 2009 Kow, CI: -211 to -52) Boerman I, BMC Vet Res,
8 !29! Give Up? Yeah, used to be...!32 286
9 !33 363!34 412!35 440!36 475
10 !37 501! Lee KW et al., Cancer, 2003
11 41 Lee KW et al., Cancer,
12 45 46 n CR CR 9 50% 5 Jeglum KA, JAVMA, % 7.1 Mahony OM, JAVMA, Vail DM, JVIM, % 4.7 Zwahlen CH, JAVMA, % 8.2 Teske E, JVIM, % 34.8 Limmer S, VCO, % 1.7PFI Collette SA, VCO, 2015 * CHOP 47!48 n=20 Gouldin ED, VCO, 2015
13 49 Rassnick KM, JAVMA, Dank G, Vet Comp Oncol, % 1. Moore AS, J Vet Intern Med. 1990, 2. Chun R, J Am Vet Med Assoc. 1996, 3. Knapp DW, Cancer Chemother Pharmacol. 2000, 4. Chun R, Vet Intern Med. 1997, 5. Knapp DW, J Vet Intern Med. 1994, 6. Mutsaers AJ, J Vet Intern Med. 2003, 7. Knapp DW, J Vet Intern Med. 2013, 9. Arnold EJ, J Vet Intern Med. 2011, 12. Robat C, J Small Anim Pract. 2013, 13. Mohammed SI, Cancer Res. 2002, 14. Mohammed SI, Mol Cancer Ther. 2003, 15. Boria PA, Vet Comp Oncol. 2005, 16. Greene SN, J Am Vet Med Assoc. 2007, 18. Marconato L, J Am Vet Med Assoc. 2011, 19. Kaye ME, Vet Comp Oncol. 2013, 20. Schrempp DR, J Am Vet Med Assoc. 2013, 21. Henry CJ, Clin Cancer Res. 2003, 22. Knapp DW, Small Animal Clinical Oncology (5 th ed), 2013, 23. Perazella MA, Semin Nephrol. 2010, 24. Rao P, J Pharm Pharm Sci. 2008, 25. Allstadt SD, J Vet Intern Med 2015, 26. Knapp DW, ILAR J % 1. Moore AS, J Vet Intern Med. 1990, 2. Chun R, J Am Vet Med Assoc. 1996, 3. Knapp DW, Cancer Chemother Pharmacol. 2000, 4. Chun R, Vet Intern Med. 1997, 5. Knapp DW, J Vet Intern Med. 1994, 6. Mutsaers AJ, J Vet Intern Med. 2003, 7. Knapp DW, J Vet Intern Med. 2013, 9. Arnold EJ, J Vet Intern Med. 2011, 12. Robat C, J Small Anim Pract. 2013, 13. Mohammed SI, Cancer Res. 2002, 14. Mohammed SI, Mol Cancer Ther. 2003, 15. Boria PA, Vet Comp Oncol. 2005, 16. Greene SN, J Am Vet Med Assoc. 2007, 18. Marconato L, J Am Vet Med Assoc. 2011, 19. Kaye ME, Vet Comp Oncol. 2013, 20. Schrempp DR, J Am Vet Med Assoc. 2013, 21. Henry CJ, Clin Cancer Res. 2003, 22. Knapp DW, Small Animal Clinical Oncology (5 th ed), 2013, 23. Perazella MA, Semin Nephrol. 2010, 24. Rao P, J Pharm Pharm Sci. 2008, 25. Allstadt SD, J Vet Intern Med 2015, 26. Knapp DW, ILAR J. 2014
14 53 % 1. Moore AS, J Vet Intern Med. 1990, 2. Chun R, J Am Vet Med Assoc. 1996, 3. Knapp DW, Cancer Chemother Pharmacol. 2000, 4. Chun R, Vet Intern Med. 1997, 5. Knapp DW, J Vet Intern Med. 1994, 6. Mutsaers AJ, J Vet Intern Med. 2003, 7. Knapp DW, J Vet Intern Med. 2013, 9. Arnold EJ, J Vet Intern Med. 2011, 12. Robat C, J Small Anim Pract. 2013, 13. Mohammed SI, Cancer Res. 2002, 14. Mohammed SI, Mol Cancer Ther. 2003, 15. Boria PA, Vet Comp Oncol. 2005, 16. Greene SN, J Am Vet Med Assoc. 2007, 18. Marconato L, J Am Vet Med Assoc. 2011, 19. Kaye ME, Vet Comp Oncol. 2013, 20. Schrempp DR, J Am Vet Med Assoc. 2013, 21. Henry CJ, Clin Cancer Res. 2003, 22. Knapp DW, Small Animal Clinical Oncology (5 th ed), 2013, 23. Perazella MA, Semin Nephrol. 2010, 24. Rao P, J Pharm Pharm Sci. 2008, 25. Allstadt SD, J Vet Intern Med 2015, 26. Knapp DW, ILAR J
15 !57!58 60
16 61 Berg J, Cancer, n= 102) mg/m 2 IV 60mg/m 2 ) IV 23 x 3 Berg J, Cancer, n vs. P< vs. 10p=0.727 Berg J, Cancer, Berg J, Cancer, 1997
17 65 Berg J, Cancer,
分子標的薬アプデート 2018
Primary imatinib, 2002-2008 (CML IV) 5-year survival 93% n = 2830 Survival probability IFN or SCT, 1997-2008 (CML IIIA) 5-year survival 71% IFN or SCT, 1995-2008 (CML III) 5-year survival 63% IFN, 1986-2003
437“ƒ
et al., et al., et al., et al., et al., et al., 2 et al., et al., et al., Lancet Pharmacol Res. et al. Jpn J Cancer Res. et al. Jpn J Cancer Res. et al. Tohoku J Exp Med. et al. Jpn Circ J. et al. Cancer
日本皮膚科学会雑誌第122巻第2号
J Dermatol Sci Vitam Horm NEnglJMed Lancet J Clin Invest Antitoxid Redox Signal Diabetes Metab Res Rev Diabetes Care Diabet Med Diabetes care Diabetes Care J Foot Ankle Surg Wound Repair Regen Lancet Foot
untitled
37 70,500 135,000 27,700 11 37,400 60,400 8,900 5 40,900 64,900 26,600 4 40,100 47,200 29,700 2 30,500 37,100 24,000 36 62,800 132,000 4,800 20 50,800 72,300 10,800 60 2 7 12 17 67,900 74,872 80,133 83,500
日本皮膚科学会第121巻第9号
Appl Nurs Res Wound Repair Regen Int Wound J Adv Skin Wound Care Ostomy Wound Manage Wound Repair Regen Int J Nurs Stud JAdvNurs Visual Dermatology J Adv Nurs Appl Nurs Res Cochrane Database Syst Rev
E3200 BV FOLFOX4 FOLFOX4 PFS % 0.42, 0.65 p< log-rank % FOLFOX4 8.6% FOLFOX % FOLFOX4 259/ % FOL
E3200 BV FOLFOX4 FOLFOX4 PFS 4.5 7.5 0.518 95% 0.42, 0.65 p
untitled
NPO 2006( ) 11 14 ( ) (2006/12/3) 1 50% % - - (CO+H2) ( ) 6 44 1) --- 2) ( CO H2 ) 2 3 3 90 3 3 2 3 2004 ( ) 1 1 4 1 20% 5 ( ) ( ) 2 6 MAWERA ) MAWERA ( ) ( ) 7 6MW -- 175kW 8 ( ) 900 10 2 2 2 9 -- - 10
untitled
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Int J Radiat Oncol Biol Phys 49 Cancer 101 Int J Radiat Oncol Biol Phys 60 Chest 124 Int J Radiat Oncol Biol Phys 56 Int J Radiat Oncol Biol Phys 49 Chest 124 Int J
2009 Aida et al. Caries Res 2006;40 2000 100 % 78.7 88.0 96.6 98.8 98.8 98.8 100.0 100.0 100 75 69.4 50 75.3 74.8 73.3 73.1 73.0 72.4 71.8 71.7 51.7 40.2 69.4 68.8 73.6 25 22.3 32.8 21.9 22.9 22.1
物理化学I-第12回(13).ppt
I- 12-1 11 11.1 2Mg(s) + O 2 (g) 2MgO(s) [Mg 2+ O 2 ] Zn(s) + Cu 2+ (aq) Zn 2+ (aq) + Cu(s) - 2Mg(s) 2Mg 2+ (s) + 4e +) O 2 (g) + 4e 2O 2 (s) 2Mg(s) + O 2 (g) 2MgO(s) Zn(s) Zn 2+ (aq) + 2e +) Cu 2+ (aq)
特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書（案）
VOL.51 NO.6 JUNE 2003 JUNE 2003 9) Niederman MS et al: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention.
取扱説明書 ［F-05E］
F-05E 12.11 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 a b 22 c d e 23 24 a o c d a b p q b o r s e f h i j k l m g f n a b c d e f g h 25 i j k l m n o p q r s a X b SD 26 27 28 X 29 a b c
スライド 1
QOL 1 Goldberg, JCO 22:23-30, 2004 N9741: Oxaliplatin in First Line (US) IR 200 mg/m 2 OX 85 mg/m 2 every 3 weeks Efficacy IFL FOLFOX4 > IFL IROX FOLFOX4 IROX OS TTP RR 15.0 mo 6.9 mo 31 % P=0.0001 P=0.0014
空き容量一覧表（154kV以上）
1/3 A. 電気所 ( 発電所, 変電所, 配電塔 ) における変圧器の空き容量 覧 < 留意事項 > (1) 空容量は 安であり 系統接続の前には 接続検討のお申込みによる詳細検討が必要となります その結果 空容量が変更となる場合があります (2) 熱容量を考慮した空き容量を記載しております その他の要因 ( や系統安定度など ) で連系制約が発 する場合があります (3) 表 は 既に空容量がないため
Atlas_j060419
Hill s Atlas of Veterinary Clinical Anatomy 1 29 30 2 3 4 5 31 32 33 34 35 36 37 6 7 8 9 10 11 12 13 38 39 40 41 14 15 16 17 18 19 20 21 22 23 24 25 26 27 42 43 44 45 46 47 48 49 50 51 52 53 54 55 28 81
2/8 一次二次当該 42 AX 変圧器 なし 43 AY 変圧器 なし 44 BA 変圧器 なし 45 BB 変圧器 なし 46 BC 変圧器 なし
1/8 A. 電気所 ( 発電所, 変電所, 配電塔 ) における変圧器の空き容量一覧 < 留意事項 > (1) 空容量は目安であり 系統接続の前には 接続検討のお申込みによる詳細検討が必要となります その結果 空容量が変更となる場合があります (2) 特に記載のない限り 熱容量を考慮した空き容量を記載しております その他の要因 ( や系統安定度など ) で連系制約が発生する場合があります (3)
終末期の呼吸困難症状への対応*松坂最終修正
Clinical Question 2017 5 27 1 PCOC 1. 12778 ( 55%, 45% NRS. 1 54, 35%. NRS. NRS,,,,,,,, Performance status, Ekstrom, M., et al.2016 J Pain Symptom Manage 51(5):816-23. . 1 85 ADL. 3,,,,. JCS200,, 40 /,
日本皮膚科学会雑誌第121巻第11号
β Clin Rheumatol Arthritis Rheum Am J Cardiol J Rheumatol J Rheumatol Arthritis Rheum Arthritis Rheum Arthritis Rheum Rheumatology Oxford Rheumatology Oxford Br J Dermatol Arch Dermatol Ann Rheum Dis
CRA3689A
AVIC-DRZ90 AVIC-DRZ80 2 3 4 5 66 7 88 9 10 10 10 11 12 13 14 15 1 1 0 OPEN ANGLE REMOTE WIDE SET UP AVIC-DRZ90 SOURCE OFF AV CONTROL MIC 2 16 17 1 2 0 0 1 AVIC-DRZ90 2 3 4 OPEN ANGLE REMOTE SOURCE OFF
19 3 6 4 65 50 2 1 25.018.716.2 15.0 7 70.17.9 8 44.242.3 50.6 5 23.3 35.7 2 1 (SA) 2 (SA) 6 4 3 (SA) PTA 4 (SA) 7 50 5 (SA) 4 6 (3 ) 7 (SA) 8 2 1 8 3 30 50 9 (SA) 5 60 10 (SA) 2 11 (SA) 12 (MA) 40 13
CAR-T実施
Building a Clinical CAR-T Program - Jichi Medical University Experience l l l Anti-CD3/28 mabs & IL-2: 29% Anti-CD3/28 beads: 66% Retroviral: 41% Lentiviral: 54% T-Flasks: 22% Static Culture Bags: 35%
32 1 BRONJ BRONJ II BRONJ BRONJ 4 BP BRONJ 6 1 III BP BRONJ
29 1 31 40 2014 31 Bisphosphonate related osteonecrosis of jaw; BRONJ 2008 4 2012 3 36 98 8 11 19 BRONJ 0 13 2 5 3 1 1 0 BP 4 15 10 5 α-streptococcus 0 BRONJ BRONJ BP I Paget 1 409-3898 1110 2014 1 27
VOL33NO.3/2010 A B A B p-erk1/2 Time (min) 0 1 2 5 10 15 30 60 90 120 Erk1/2 Time (min) 0 1 2 5 10 15 30 60 90 120 p-vasp VASP C D enos/gapdh x-fold vs sham 2.0 1.5 1.0 0.5 * 0 ANP (-) (+) (-)
DM
( ) FAX DM DM PR 300 - - - - - - - - - - - - - - - - - - 6 3 1 4 3 - - - - PR P173 FAX (2001) (2000) (1999) 1986 http://kimono-yamato.com/04-kiso/qa.html Q&A http://web.sfc.keio.ac.jp/~t00524sh/chousa/rich/kimonobegin.html
<90CE90EC88E290D55F955C8E862E656336>
5 5 9 9 7 7 5 5 6 6 7 7 8 8 9 9 8 8 8 8 79 79 78 78 76 76 77 77 7 7 6 7 7 5 68 68 67 67 66 66 65 65 6 6 6 6 6 6 6 6 6 6 59 59 58 58 57 57 56 56 55 55 5 5 8 8 5 5 9 9 9 8 7 9 9 8 8 7 7 6 6 5 5 5 5 69 69
The Heart Healthy Tocotrienol Complex Tocomin SupraBio
The Heart Healthy Tocotrienol Complex Tocomin SupraBio The Heart Healthy Tocotrienol Complex Tocomin SupraBio 1. Fact Sheet No. 317; World Health Organization (WHO), 2007 2. LLOYD-JONES D. et al. Circulation
10 2 2 10 6.5 78 1 65 / 30 / - 2 -
- 1 - 10 2 2 10 6.5 78 1 65 / 30 / - 2 - 3 3 30 8 4 8 6 11 14 45 14 7 8 1-3 - 4 1 () 20 4 9 4 9 3 9 4 PR 4 3-4 - - 5 - PR 15 4 PR 7 8 4 9 10-6 - 9 10 9 10 4 9 10 3 9 10 9 9 9 10 PR 1-7 - PR - 8 - 30 100-9
10K1A NASA () SPACE ATLAS Freedom H2A NASA 1
10O1A 10 10 1 10K1A NASA () SPACE ATLAS 40 1957 1969 10 1986 1990 Freedom 20 000 H2A NASA 1 10K1A 100 10 21 40 1996 ( 200 () 2 10S1A 10 8 57 250 1 10S1A 20 200mmm 2 10S1B 18 18 1 10S1B 40 10 20 2 10S1C
卵巣癌の治療
K-net:2008.7.17 85 90 8 10 20 (FIGO) a (FIGO) b (FIGO) c (FIGO) a (FIGO) b (FIGO) c (FIGO) (FIGO) (FIGO) Risk factors Preventive factors Risk factors 35 PCO, Preventive factors? Relative risk
1/68 A. 電気所 ( 発電所, 変電所, 配電塔 ) における変圧器の空き容量一覧 平成 31 年 3 月 6 日現在 < 留意事項 > (1) 空容量は目安であり 系統接続の前には 接続検討のお申込みによる詳細検討が必要となります その結果 空容量が変更となる場合があります (2) 特に記載
1/68 A. 電気所 ( 発電所, 変電所, 配電塔 ) における変圧器の空き容量一覧 平成 31 年 3 月 6 日現在 < 留意事項 > (1) 空容量は目安であり 系統接続の前には 接続検討のお申込みによる詳細検討が必要となります その結果 空容量が変更となる場合があります (2) 特に記載のない限り 熱容量を考慮した空き容量を記載しております その他の要因 ( 電圧や系統安定度など ) で連系制約が発生する場合があります
1 2 1 3 2 4 22 NPO PR NPO NPO 22 10 4 2,000kg 1kg 5 2 1 4,000 20,000 26 33 27 24 3 19 24 3 4 3 4 3 () 34 3 4 5 23 3 17 23 20 30 1 1 877g/ 3 24 3 1 1 28 897g/ 33 850g/ 22 23 30 1 1 510g/ 22 23 3 24
取扱説明書
ED-601 ED-501 ED-401 2 3 4 23 14 5 6 18 10 7 1 2 6 3 4 8 9 16 16 16 12 1 2 18 10 2 1 5 12 11 1 2 1 2 12 1 2 13 16 14 3 2 4 1 1 2 16 3 4 18 15 1 2 16 2 3 1 1 2 3 18 17 18 22 19 D A C 20 A B 22 B C D 22
Various function and toxicity of iron Key words 1) Hentze, M. W. et al: Cell, 117, 285-297 (2004) 2) Ganz, T.: Blood, 102, 783-788 (2003) 3) Nemeth, E. et al.: Science, 306, 2090-2093 (2004) 4) Hentze,
3675-433897418-1.pdf
A : : : : : : : : : : PR PR NHK 2 PR PR 3 1954 7 4 5 9 12,000 12 100 2 2 11 4 5 6 7 / PR 8 9 10 11 1952 ( ) 2008 2009 2012 NHK km m m 12 m km km kg kg 13 % 14 15 1959 5 20 8 17100kg 400kg How much? 60
近畿中国四国農業研究センター研究報告 第７号
230 C B A D E 50m 558 0 1km (mg L 1 ) T N NO 2 3 N NH 4 N 2.0 0 (a) 2001 1.5 6 20 21 5 1.0 0.5 0.0 2.0 1.5 1.0 0.5 0.0 14:00 17:00 (b) 2001 7 3 4 20:00 23:00 2:00 (h) 5:00 8:00 11:00 10 0 5 10 15
42 3 u = (37) MeV/c 2 (3.4) [1] u amu m p m n [1] m H [2] m p = (4) MeV/c 2 = (13) u m n = (4) MeV/c 2 =
![42 3 u = (37) MeV/c 2 (3.4) [1] u amu m p m n [1] m H [2] m p = (4) MeV/c 2 = (13) u m n = (4) MeV/c 2 =](/thumbs/73/68712188.jpg "42 3 u = (37) MeV/c 2 (3.4) [1] u amu m p m n [1] m H [2] m p = (4) MeV/c 2 = (13) u m n = (4) MeV/c 2 =")
3 3.1 3.1.1 kg m s J = kg m 2 s 2 MeV MeV [1] 1MeV=1 6 ev = 1.62 176 462 (63) 1 13 J (3.1) [1] 1MeV/c 2 =1.782 661 731 (7) 1 3 kg (3.2) c =1 MeV (atomic mass unit) 12 C u = 1 12 M(12 C) (3.3) 41 42 3 u
ライフサイエンス関連 コラーゲン・ゼラチン製品案内 2015.12
3 mg/ml ph 3 4 8 1 Type I-A Type I-P Type I-A Type I-C Type III Type III Type IV Type IV TEL 072-820-3079 FAX 072-820-3095 4 8 4 Type I-A 20mL 1 F-12 MEM 5mL 1 4mL 5 10F-12MEM DFDME F-12 1 1199 5 DMERPMI-1640
【知事入れ版】270804_鳥取県人口ビジョン素案
7 6 5 4 3 2 1 65 1564 14 192 193 194 195 196 197 198 199 2 21 22 23 24 1.65 1,4 1.6 1,2 1.55 1, 1.45 6 1.5 8 1.4 4 1.35 1.3 2 27 28 29 21 211 212 213 214 6 5 4 3 2 1 213 218 223 228 233 238 243 248 253
表1.eps
Vol.1 C ontents 1 2 cell-free EMBO J Proc. Natl. Acad. Sci. USA NatureEMBO J 3 RNA NatureEMBO J Nature EMBO J 4 5 HCV HCV HCV HCV RNA HCV in situ 6 7 8 Nat Struct Mol Biol J Biol Chem Nat Commun J Virol
O-1 O-2 O-3 O-4 O-5 O-6
18 The 18 th Congress of Hokkaido Association for Clinical Engineering Technologists 930940 O-1 O-2 O-3 O-4 O-5 O-6 O-7 O-8 O-9 O-10 O-11 O-12 O-13 O-14 O-15 O-16 O-17 O-18 O-19 O-20 O-21 O-22 O-23 O-24
![かんたん操作ガイド[arrows M02]](/thumbs/39/20071242.jpg "かんたん操作ガイド[arrows M02]")
![かんたん操作ガイド[arrows RM02]](/thumbs/39/20475147.jpg "かんたん操作ガイド[arrows RM02]")
![かんたん操作ガイド[arrows M03]](/thumbs/42/22941141.jpg "かんたん操作ガイド[arrows M03]")
JA2008
A1 1 10 vs 3 2 1 3 2 0 3 2 10 2 0 0 2 1 0 3 A2 3 11 vs 0 4 4 0 0 0 0 0 3 6 0 1 4 x 11 A3 5 4 vs 5 6 5 1 0 0 3 0 4 6 0 0 1 0 4 5 A4 7 11 vs 2 8 8 2 0 0 0 0 2 7 2 7 0 2 x 11 A5 9 5 vs 3 10 9 4 0 1 0 0 5
1
I II II 1 dw = pd = 0 1 U = Q (4.10) 1K (heat capacity) (mole heat capacity) ( dq / d ) = ( du d C = / ) (4.11) du = C d U = C d (4.1) 1 1 du = dq + dw dw = pd dq = du + pd (4.13) p dq = d( U + p ) p (4.14)
(1) (2) (1) (2) (1) Seg (2) Seg (3) Seg (4) Seg (1) (2) (3) ( ) (1) (PCA)...12
(1)...109 (2)...110 (1) 28...111 (2) 28...113 (1) Seg...115 (2) Seg...117 (3) Seg...119 (4) Seg...120 (1)...122 (2)...122 (3) ( )...126 (1) (PCA)...127 (2) Draize...128 (1) Ames...129 2 in vitro...132
野岩鉄道の旅
29th 5:13 5:34 5:56 6:00 6:12 6:20 6:21 6:25 6:29 6:31 6:34 6:38 6:40 6:45 6:52 6:56 7:01 7:07 7:11 7:32 7:34 7:50 7:58 8:03 8:17 8:36 8:44 5:50 5:54 6:15 6:38 6:39 6:51 6:59 6:59 7:03 7:08 7:08 7:11 7:15
1
1 5% 4% 11% 8% 13% 12% 10% 6% 17% 6% 8% 4% 6% 6% 2% 17% 17% 12% 14% 16% 6% 37% 11% 17% 35% 2 (N=6,239) 0 200 400 600 800 1,000 1,200 1,400 1,600 1,800 1,585 1,126 950 494 345 296 242 263 191 150 131 116
37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate
37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5
77 http//www.pref.nara.jp/rinsei/bio/biotop.htm 1... 1 2... 2 3... 3 4... 4 5 1... 5 6 2... 6 7 3... 7 8 4... 8 9... 9 1... 1 11... 12 12... 14 13... 16 14... 18 15... 2 16... 22 17 1... 24 18 2... 26
1 2030 2 3 2030 2030 3 10,000 4 2010 9 27 10 18 5 6 100 7 3 20 30 20 30 30 30 2 8 31.6 30.7 22.6 15.0 29.7 29.7 23.6 17.0 45.2% n=10000 54.8% 33.9 31.9 21.5 12.7 9.7 2024 3034 2529 3539 19.0% n=10000 n=10000
36 th IChO : - 3 ( ) , G O O D L U C K final 1
36 th ICh - - 5 - - : - 3 ( ) - 169 - -, - - - - - - - G D L U C K final 1 1 1.01 2 e 4.00 3 Li 6.94 4 Be 9.01 5 B 10.81 6 C 12.01 7 N 14.01 8 16.00 9 F 19.00 10 Ne 20.18 11 Na 22.99 12 Mg 24.31 Periodic
2001 Mg-Zn-Y LPSO(Long Period Stacking Order) Mg,,,. LPSO ( ), Mg, Zn,Y. Mg Zn, Y fcc( ) L1 2. LPSO Mg,., Mg L1 2, Zn,Y,, Y.,, Zn, Y Mg. Zn,Y., 926, 1
Mg-LPSO 2566 2016 3 2001 Mg-Zn-Y LPSO(Long Period Stacking Order) Mg,,,. LPSO ( ), Mg, Zn,Y. Mg Zn, Y fcc( ) L1 2. LPSO Mg,., Mg L1 2, Zn,Y,, Y.,, Zn, Y Mg. Zn,Y., 926, 1 1,.,,., 1 C 8, 2 A 9.., Zn,Y,.